Edition:
United States

argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

82.30EUR
21 May 2018
Change (% chg)

-- (--)
Prev Close
€82.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
45,558
52-wk High
€83.70
52-wk Low
€16.75

Chart for

About

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused... (more)

Overall

Beta: 0.59
Market Cap(Mil.): €2,602.47
Shares Outstanding(Mil.): 32.17
Dividend: --
Yield (%): --

Financials

  ARGX.BR Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -1.23 -- --
ROI: -- -8.07 12.63
ROE: -- -10.87 14.50

BRIEF-Argenx Q1 Operating Income Down At 6.9 Million Euros

* ARGENX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 09 2018

BRIEF-Argenx To Present Complete Data From Phase 2 Proof-Of-Concept Trial Of Efgartigimod (Argx-113)

* REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING

Apr 24 2018

BRIEF-Argenx To Receive Third Preclinical Milestone Payment From Collaboration With Leo Pharma

* TO RECEIVE THIRD PRECLINICAL MILESTONE PAYMENT FROM COLLABORATION WITH LEO PHARMA - MILESTONE ASSOCIATED WITH CTA APPROVAL FOR ARGX

Apr 12 2018

BRIEF-Argenx Appoints Keith Woods As Chief Operating Officer

* ARGENX APPOINTS KEITH WOODS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 09 2018

BRIEF-Argenx Appoints Keith Woods As Chief Operating Officer

* ARGENX APPOINTS KEITH WOODS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 09 2018

BRIEF-Argenx ‍To Present Complete Data From Phase 2 Clinical Trial Of Efgartigimod

* ‍TO PRESENT COMPLETE DATA FROM PHASE 2 CLINICAL TRIAL OF EFGARTIGIMOD (ARGX-113) IN MYASTHENIA GRAVIS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 03 2018

BRIEF-Argenx ‍Announces Orphan Drug Designation For Argx-113 For Treatment Of Myasthenia Gravis In Europe​

* ‍ANNOUNCES ORPHAN DRUG DESIGNATION FOR ARGX-113 FOR TREATMENT OF MYASTHENIA GRAVIS IN EUROPE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 26 2018

BRIEF-Argenx Reports Fourth Quarter Business Update And Full Year 2017 Financial Results

* ARGENX REPORTS FOURTH QUARTER BUSINESS UPDATE AND FULL YEAR 2017 FINANCIAL RESULTS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 01 2018

BRIEF-Argenx FY Total Operating Income Rises To 41.3 Million Euros

* FY REVENUE EUR 36.4‍​ MILLION VERSUS EUR 14.7 MILLION YEAR AGO

Mar 01 2018

BRIEF-Argenx Announces Updated Size Of Proposed Public Offering In The U.S. To 3.5 Million ADSS

* HAS UPDATED NUMBER OF AMERICAN DEPOSITARY SHARES ("ADSS") IN ITS UNDERWRITTEN U.S. PUBLIC OFFERING (OFFERING) TO 3.5 MILLION ADSS

Dec 13 2017

Earnings vs. Estimates